Year |
Citation |
Score |
2015 |
Christner SM, Clausen DM, Beumer JH, Parise RA, Guo J, Huang Y, Dömling AS, Eiseman JL. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction. Cancer Chemotherapy and Pharmacology. PMID 26050209 DOI: 10.1007/S00280-015-2791-Y |
0.334 |
|
2014 |
Boltjes A, Huang Y, van de Velde R, Rijkee L, Wolf S, Gaugler J, Lesniak K, Guzik K, Holak TA, Dömling A. Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor. Acs Combinatorial Science. 16: 393-6. PMID 24983416 DOI: 10.1021/Co500026B |
0.4 |
|
2014 |
Huang Y, Wolf S, Beck B, Köhler LM, Khoury K, Popowicz GM, Goda SK, Subklewe M, Twarda A, Holak TA, Dömling A. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. Acs Chemical Biology. 9: 802-11. PMID 24405416 DOI: 10.1021/Cb400728E |
0.387 |
|
2013 |
Bista M, Wolf S, Khoury K, Kowalska K, Huang Y, Wrona E, Arciniega M, Popowicz GM, Holak TA, Dömling A. Transient protein states in designing inhibitors of the MDM2-p53 interaction. Structure (London, England : 1993). 21: 2143-51. PMID 24207125 DOI: 10.1016/J.Str.2013.09.006 |
0.368 |
|
2012 |
Huang Y, Khoury K, Chanas T, Dömling A. Multicomponent synthesis of diverse 1,4-benzodiazepine scaffolds. Organic Letters. 14: 5916-9. PMID 23157402 DOI: 10.1021/Ol302837H |
0.304 |
|
2012 |
Koes D, Khoury K, Huang Y, Wang W, Bista M, Popowicz GM, Wolf S, Holak TA, Dömling A, Camacho CJ. Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. Plos One. 7: e32839. PMID 22427896 DOI: 10.1371/Journal.Pone.0032839 |
0.397 |
|
2012 |
Huang Y, Wolf S, Koes D, Popowicz GM, Camacho CJ, Holak TA, Dömling A. Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. Chemmedchem. 7: 49-52. PMID 21954050 DOI: 10.1002/Cmdc.201100428 |
0.371 |
|
2011 |
Huang Y, Dömling A. The Gewald multicomponent reaction. Molecular Diversity. 15: 3-33. PMID 20191319 DOI: 10.1007/S11030-010-9229-6 |
0.318 |
|
2010 |
Czarna A, Beck B, Srivastava S, Popowicz GM, Wolf S, Huang Y, Bista M, Holak TA, Dömling A. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angewandte Chemie (International Ed. in English). 49: 5352-6. PMID 20575124 DOI: 10.1002/Anie.201001343 |
0.387 |
|
2010 |
Huang Y, Dömling A. 1,4-Thienodiazepine-2,5-diones via MCR (II): scaffold hopping by Gewald and Ugi-deprotection-cyclization strategy. Chemical Biology & Drug Design. 76: 130-41. PMID 20545946 DOI: 10.1111/J.1747-0285.2010.00990.X |
0.372 |
|
2010 |
Huang Y, Wolf S, Bista M, Meireles L, Camacho C, Holak TA, Dömling A. 1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chemical Biology & Drug Design. 76: 116-29. PMID 20492448 DOI: 10.1111/J.1747-0285.2010.00989.X |
0.41 |
|
2010 |
Dömling A, Huang Y. Piperazine scaffolds via isocyanide-based multicomponent reactions Synthesis. 2010: 2859-2883. DOI: 10.1055/S-0030-1257906 |
0.386 |
|
2009 |
Wang K, Nguyen K, Huang Y, Dömling A. Cyanoacetamide multicomponent reaction (I): Parallel synthesis of cyanoacetamides. Journal of Combinatorial Chemistry. 11: 920-7. PMID 19694451 DOI: 10.1021/Cc9000778 |
0.324 |
|
Show low-probability matches. |